SOX9表达在胃癌中的临床病理及预后意义：荟萃分析与TCGA分析

The Clinicopathological and Prognostic Significance of SOX9 Expression in Gastric Cancer: Meta-Analysis and TCGA Analysis.

作者信息

Zu Guo, Gao Jiacheng, Zhou Tingting

机构信息

Department of Gastrointestinal Surgery, The Dalian Municipal Central Hospital Affiliated to Dalian Medical University, Dalian, China.

Department of Graduate School, Dalian Medical University, Dalian, China.

出版信息

Front Oncol. 2021 Sep 9;11:668946. doi: 10.3389/fonc.2021.668946. eCollection 2021.

DOI:10.3389/fonc.2021.668946

PMID:34568009

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8458960/

Abstract

BACKGROUND

The clinicopathological and prognostic significance of SRY-box transcription factor 9 (SOX9) expression in gastric cancer (GC) patients is still controversial. Our aim is to investigate the clinicopathological and prognostic value of SOX9 expression in GC patients.

METHODS

A systemic literature search and meta-analysis were used to evaluate the clinicopathological significance and overall survival (OS) of SOX9 expression in GC patients. The Cancer Genome Atlas (TCGA) dataset was used to investigate the relationship between SOX9 expression and OS of stomach adenocarcinoma (STAD) patients.

RESULTS

A total of 11 articles involving 3,060 GC patients were included. In GC patients, the SOX9 expression was not associated with age [odds ratio (OR) = 0.743, 95% CI = 0.507-1.089, p = 0.128], sex (OR = 0.794, 95% CI = 0.605-1.042, p = 0.097), differentiation (OR = 0.728, 95% CI = 0.475-1.115, p = 0.144), and lymph node metastasis (OR = 1.031, 95% CI = 0.793-1.340, p = 0.820). SOX9 expression was associated with depth of invasion (OR = 0.348, 95% CI = 0.247-0.489, p = 0.000) and TNM stage (OR = 0.428, 95% CI = 0.308-0.595, p = 0.000). The 1-year OS (OR = 1.507, 95% CI = 1.167-1.945, p = 0.002), 3-year OS (OR = 1.482, 95% CI = 1.189-1.847, p = 0.000), and 5-year OS (OR = 1.487, 95% CI = 1.187-1.862, p = 0.001) were significantly shorter in GC patients with high SOX9 expression. TCGA analysis showed that SOX9 was upregulated in STAD patients compared with that in normal patients (p < 0.001), and the OS of STAD patients with a high expression of SOX9 is poorer than that in patients with low expression of SOX9, but the statistical difference is not obvious (p = 0.31).

CONCLUSION

SOX9 expression was associated with the depth of tumor invasion, TNM stage, and poor OS of GC patients. SOX9 may be a potential prognostic factor for GC patients but needs further study.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO, ID NUMBER 275712.

摘要

背景

胃癌（GC）患者中，SRY盒转录因子9（SOX9）表达的临床病理及预后意义仍存在争议。我们的目的是研究SOX9表达在GC患者中的临床病理及预后价值。

方法

采用系统文献检索和荟萃分析来评估GC患者中SOX9表达的临床病理意义及总生存期（OS）。利用癌症基因组图谱（TCGA）数据集研究胃腺癌（STAD）患者中SOX9表达与OS的关系。

结果

共纳入11篇涉及3060例GC患者的文章。在GC患者中，SOX9表达与年龄[比值比（OR）=0.743，95%置信区间（CI）=0.507-1.089，p=0.128]、性别（OR=0.794，95%CI=0.605-1.042，p=0.097）、分化程度（OR=0.728，95%CI=0.475-1.115，p=0.144）及淋巴结转移（OR=1.031，95%CI=0.793-1.340，p=0.820）均无关联。SOX9表达与浸润深度（OR=0.348，95%CI=0.247-0.489，p=0.000）及TNM分期（OR=0.428，95%CI=0.308-0.595，p=0.000）相关。SOX9高表达的GC患者1年总生存期（OR=1.507，95%CI=1.167-1.945，p=0.002）、3年总生存期（OR=1.482，95%CI=1.189-1.847，p=0.000）及5年总生存期（OR=1.487，95%CI=1.187-1.862，p=0.001）均显著缩短。TCGA分析显示，与正常患者相比，STAD患者中SOX9上调（p<0.001），且SOX9高表达的STAD患者的总生存期比SOX9低表达患者差，但统计学差异不明显（p=0.31）。